NVS

Novartis
NYSE

Real-time Quotes | Nasdaq Last Sale

83.42
-0.73
-0.87%
After Hours: 83.70 +0.28 +0.34% 17:20 08/05 EDT
OPEN
84.21
PREV CLOSE
84.15
HIGH
84.37
LOW
83.32
VOLUME
1.07M
TURNOVER
--
52 WEEK HIGH
99.84
52 WEEK LOW
69.18
MARKET CAP
190.95B
P/E (TTM)
26.60
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NVS stock price target is 101.00 with a high estimate of 105.00 and a low estimate of 97.00.

EPS

NVS News

More
Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis
* Ofatumumab is a targeted B-cell therapy that delivers superior efficacy with a similar safety profile when compared with teriflunomide, a commonly prescribed oral treatment for multiple sclerosis1   * ASCLEPIOS I and II demonstrated significant reductions
GlobeNewswire · 1h ago
Incyte Earnings Soar 65%, Easily Beating Views
Incyte earnings and revenue rose much more than expected. The biotech reaffirmed guidance. INCY stock was not yet active early Tuesday.
Investor's Business Daily · 1d ago
3 Stocks With Low Forward Price-Earnings Ratios
H&R; Block Inc tops the list Continue reading...
GuruFocus.com · 1d ago
Novartis Announces Kymriah Meets Primary Endpoint at Interim Analysis of Pivotal Study in Follicular Lymphoma
Novartis (NYSE: NVS) today announced positive results from the Phase II ELARA trial of Kymriah® (tisagenlecleucel) in patients with relapsed or refractory (r/r) follicular lymphoma (FL).
Benzinga · 1d ago
Novartis announces Kymriah® meets primary endpoint at interim analysis of pivotal study in follicular lymphoma
* Global ELARA trial demonstrated clinically meaningful benefit in patients with relapsed or refractory (r/r) follicular lymphoma (FL) as measured by complete response rate   * Kymriah previously received FDA Regenerative Medicine Advanced Therapy (RMAT) des
GlobeNewswire · 1d ago
Novartis Stock Lifted As Psoriasis Drug Notches EU Approval
Europe granted approval for Novartis drug Cosentyx in treating moderate-to-severe plaque psoriasis in patients age 6 to under 18, after successful Phase 3 testing, sending NVS stock rising.
Investor's Business Daily · 2d ago
Novartis shares are trading higher after the company received EU approval for first-line systemic treatment in pediatric psoriasis.
Benzinga · 2d ago
Novartis Cosentyx Receives EU Approval for First-line Systemic Treatment in Pediatric Psoriasis
Novartis (NYSE: NVS) today announced the European Commission (EC) has granted the approval for Cosentyx® (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in children and adolescents aged 6 to <18 years.
Benzinga · 2d ago

Industry

Pharmaceuticals
+0.32%
Pharmaceuticals & Medical Research
+0.27%

Hot Stocks

Symbol
Price
%Change

About NVS

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.
More

Webull offers kinds of Novartis AG (ADR) stock information, including NYSE:NVS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVS stock methods without spending real money on the virtual paper trading platform.